Gyre Therapeutics Announces the Appointment of Ping Zhang to Board of Directors
06. Januar 2025 07:00 ET
|
Gyre Therapeutics, Inc.
Gyre Therapeutics Announces the Appointment of Ping Zhang to Board of Directors
Gyre Therapeutics Reports Third Quarter 2024 and Year-To-Date Financial Results and Provides Business Update
13. November 2024 06:00 ET
|
Gyre Therapeutics, Inc.
Gyre Therapeutics Reports Third Quarter 2024 and Year-To-Date Financial Results and Provides Business Update
Gyre Therapeutics Announces Last Patient Completed Pivotal Phase 3 Trial Evaluating F351 for CHB-Associated Liver Fibrosis
22. Oktober 2024 16:05 ET
|
Gyre Therapeutics, Inc.
Gyre Therapeutics Announces Last Patient Completed Pivotal Phase 3 Trial Evaluating F351 for CHB-Associated Liver Fibrosis
Gyre Therapeutics to Present at 8th Annual H.C. Wainwright MASH Investor Conference
01. Oktober 2024 16:05 ET
|
Gyre Therapeutics, Inc.
Gyre Therapeutics to Present at 8th Annual H.C. Wainwright MASH Investor Conference
Gyre Therapeutics Reports Second Quarter 2024 and Year-To-Date Financial Results and Provides Business Update
13. August 2024 06:00 ET
|
Gyre Therapeutics, Inc.
Gyre Therapeutics Reports Second Quarter 2024 and Year-To-Date Financial Results and Provides Business Update
Gyre Therapeutics to Present at Sidoti Virtual Investor Conference
09. August 2024 07:00 ET
|
Gyre Therapeutics, Inc.
Gyre Therapeutics to Present at Sidoti Virtual Investor Conference
Gyre Therapeutics Announces Appointment of David M. Epstein, Ph.D., to Board of Directors
08. August 2024 16:05 ET
|
Gyre Therapeutics, Inc.
Gyre Therapeutics Announces Appointment of David M. Epstein, Ph.D., to Board of Directors
Gyre Therapeutics Announces Publication in Journal of Gastroenterology and Hepatology
18. Juni 2024 16:05 ET
|
Gyre Therapeutics, Inc.
Gyre Therapeutics Announces Publication in Journal of Gastroenterology and Hepatology
Gyre Therapeutics Announces Expected Addition to the Russell 2000® and Russell 3000® Indexes
28. Mai 2024 16:05 ET
|
Gyre Therapeutics, Inc.
Gyre Therapeutics Announces Expected Addition to the Russell 2000® and Russell 3000® Indexes
Gyre Therapeutics Reports Full Year 2023 Financial Results and Provides Business Update
26. März 2024 06:00 ET
|
Gyre Therapeutics, Inc.
Gyre Therapeutics Reports Full Year 2023 Financial Results and Provides Business Update